Table 2.
Patients with reduced RDI by cancer type and stage (percent of patients).
| Cancer type (n,% of patients within the group) | Planned RDI < 85% | Overall actual RDI < 85% | RDI < 85% for one or more cycles | Planned RDI < 90% | Overall actual RDI < 90% | RDI < 90% for one or more cycles |
|---|---|---|---|---|---|---|
| Lymphoma (n = 459) | 22.4 | 38.9 | 48.4 | 30.1 | 48.0 | 55.8 |
| Stage I–III (n = 1946) | 21.6 | 32.7 | 43.3 | 27.0 | 41.4 | 51.1 |
| Breast (n = 1176, 60%) | 13.4 | 22.2 | 32.5 | 17.0 | 30.5 | 40.0 |
| Non-small cell lung (n = 269, 14%) | 42.0 | 63.0 | 63.9 | 52.8 | 71.3 | 75.1 |
| Small cell lung (n = 71, 4%) | 33.8 | 66.2 | 69.0 | 45.1 | 80.3 | 78.9 |
| Colorectal (n = 238, 12%) | 21.0 | 41.7 | 47.5 | 24.8 | 47.2 | 52.5 |
| Ovarian (n = 192, 10%) | 39.6 | 59.4 | 66.1 | 47.9 | 67.2 | 74.0 |
| Stage IV (n = 961) | 32.7 | 51.7 | 60.2 | 41.7 | 63.3 | 67.3 |
| Breast (n = 204, 21%) | 32.8 | 53.2 | 63.2 | 39.7 | 62.1 | 69.6 |
| Non-small cell lung (n = 344, 36%) | 30.5 | 58.8 | 59.3 | 41.0 | 66.5 | 66.6 |
| Small cell lung (n = 108, 11%) | 28.7 | 54.6 | 52.8 | 45.4 | 61.1 | 63.0 |
| Colorectal (n = 229, 24%) | 32.8 | 50.7 | 59.0 | 37.6 | 58.7 | 65.1 |
| Ovarian (n = 76, 8%) | 47.4 | 63.2 | 71.1 | 57.9 | 69.7 | 77.6 |
RDI, relative dose intensity.